We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics
BOLT

36 hedge funds and large institutions have $17M invested in Bolt Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.18% less ownership

Funds ownership: 3.15% → 2.97% (-0.18%)

3% less funds holding

Funds holding: 37 → 36 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

49% less capital invested

Capital invested by funds: $33.6M → $17M (-$16.6M)

Holders
36
Holders Change
-1
Holders Change %
-2.7%
% of All Funds
0.52%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
5
Increased
12
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$387K
2
ACM
ADAR1 Capital Management
Texas
+$179K
3
AI
Acuitas Investments
Washington
+$111K
4
Jane Street
Jane Street
New York
+$41K
5
UBS Group
UBS Group
Switzerland
+$36.1K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$2.16M
2
NM
Newtyn Management
New York
-$332K
3
Renaissance Technologies
Renaissance Technologies
New York
-$238K
4
Squarepoint
Squarepoint
New York
-$109K
5
Millennium Management
Millennium Management
New York
-$64.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Assenagon Asset Management
26
Assenagon Asset Management
Luxembourg
$25.9K +$34K +1,724 New
Morgan Stanley
27
Morgan Stanley
New York
$25.3K +$8.88K +450 +36%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$16.8K +$22.1K +1,121 New
Osaic Holdings
29
Osaic Holdings
Arizona
$11.3K – – –
SPIA
30
Steward Partners Investment Advisory
New York
$750 +$986 +50 New
JP Morgan Chase
31
JP Morgan Chase
New York
$630 – – –
Bank of America
32
Bank of America
North Carolina
$471 – – –
TRCT
33
Tower Research Capital (TRC)
New York
$138 -$5.29K -268 -97%
Barclays
34
Barclays
United Kingdom
$104 – – –
SIC
35
Salem Investment Counselors
North Carolina
$30 – – –
Qube Research & Technologies (QRT)
36
Qube Research & Technologies (QRT)
United Kingdom
$2 – – –
O
37
OrbiMed
New York
– -$2.16M -77,050 Closed
Squarepoint
38
Squarepoint
New York
– -$109K -3,901 Closed
Millennium Management
39
Millennium Management
New York
– -$64.3K -2,298 Closed
XT
40
XTX Topco
Cayman Islands
– -$18K -641 Closed
VF
41
Virtu Financial
New York
– -$15K -547 Closed
Wells Fargo
42
Wells Fargo
California
– -$295 -11 Closed
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
– +$355 +18 New
1
2

BOLT Hedge Fund Activity: Q2 2024 in Review

36 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q2 2024, worth a combined $17M — down 49% from $33.6M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of BOLT and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 12 added.

The largest buyer was Tang Capital Management, adding an estimated $387K. The largest seller was OrbiMed, exiting entirely with an estimated $2.16M sold.

  • 36 institutional investors held Bolt Biotherapeutics (BOLT) as of Q2 2024, down from 37 in Q1 2024.
  • Funds reported $17M of Bolt Biotherapeutics stock for Q2 2024, down 49% quarter-over-quarter.
  • 5 funds opened new Bolt Biotherapeutics positions in Q2 2024 and 6 closed out, a net change of -1 holder.
  • The largest Bolt Biotherapeutics buyer in Q2 2024 was Tang Capital Management, an estimated $387K added.
  • The largest Bolt Biotherapeutics seller in Q2 2024 was OrbiMed, an estimated $2.16M sold.

Based on aggregated 13F filings for Q2 2024.